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Abstract
OBJECTIVES: Transaortic transcatheter aortic valve implantation (TAo-TAVI) is a recently developed alternative to transapical (TA) or
transfemoral (TF) TAVI. We aimed to analyse the effectiveness and safety of TAo-TAVI as a first line approach and to compare it to patients
receiving TAo-TAVI as a last resort, which is current practice.
METHODS: ROUTE is a prospective, multicentre registry to assess the clinical outcomes of TAo-TAVI. Patients without contraindications
for TA- and TF-TAVI (TAo-first) were compared to patients with contraindications for both of these access routes (TAo-last). Outcome ana-
lysis was based on VARC II defined clinical end-points.
RESULTS: Three hundred and one patients were included, of which 224 patients met TAo-first and 77 TAo-last criteria. The valve was de-
livered and catheter retrieved successfully in all patients. In the TAo-first group, rates of conversion to open surgery and requirement for a
second valve were low and not different compared to TAo-last patients (1% vs. 3%, P = 0.46 and 1% vs. 3%, P = 0.46, respectively). This was
also true for the rate of paravalvular regurgitation (>_ moderate: 4% vs. 3%). All-cause mortality at 30-days was 6% vs. 5% (P = 0.76), rates of
stroke 2% vs. 0% (P = 0.24), pacemaker implantation (11% vs. 4%, P = 0.093), and life-threatening bleeding 4% vs. 3% (P = 0.70). Valve safety
(both 85%, P = 0.98) and clinical efficacy (80% vs. 82%; P = 0.73) did not differ between groups.
CONCLUSIONS: Although comparative data to TA and TF procedures were not available in the present analysis, findings suggest that TAo
may be considered not only as a last resort strategy when classical access routes are deemed unfeasible, but also as a potential first-line op-
tion, with only low rates of paravalvular regurgitation and permanent pacemaker implantation.
Clinicaltrials.gov: NCT01991431
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has become an
accepted alternative to open surgery for treating high-risk pa-
tients with severe aortic stenosis. Although different access
routes can be used for introduction of the catheter, the com-
mon femoral artery is typically preferred due to the advantages
of percutaneous access and the avoidance of a thoracic incision,
especially in high-risk patients. However, the presence of per-
ipheral vascular disease (PVD), severe vessel tortuosity, calcifica-
tion, or anatomical abnormalities of the peripheral vasculature
preclude its use in a proportion of patients [1]. Transapical (TA)
TAVI is generally used as alternative access route in patients
where transfemoral (TF) TAVI is not feasible. The recently de-
veloped transaortic (TAo) approach uses an alternative access
route, and is performed via a mini-sternotomy or anterolateral
mini-thoracotomy. It has been suggested for use in patients
with significant pulmonary disease, severely impaired left ven-
tricular (LV) function, or fragile apex [2] and has been used suc-
cessfully in patients with contraindications to TF- and TA-TAVI
[3, 4], with complications such as dissection, rupture, and bleed-
ing shown to be rare [2, 5].
The use of TAo-TAVI in patients without contraindications to
other access routes is now on the rise. This is due to surgeons
being very familiar with the insertion of catheters into the as-
cending aorta, as used in cannulation for extracorporeal circula-
tion. Additionally, approaching the procedure via the left
ventricular apex may be considered favourable by surgeons who
have experience with ventricular assist device implantation [6].
Some early studies have suggested equivalent device success and
early safety when TA and TAo procedures were compared [2, 3,
7]. Although there have been no direct comparisons between TF-
and TAo-TAVI, observational studies suggest equivalent rates of
30-day mortality and a lower rate of vascular complications with
the TAo approach [3, 5, 7–10].
Due to the lack of data on the use of alternative TAVI access
routes as a first line approach, the Registry Of the Utilisation of
the Transaortic TAVI approach using the Edwards Sapien Valve
(ROUTE) [11] was set up.
The aim of the present ROUTE registry analysis was to analyse
the safety and efficacy of TAo-TAVI as a first line approach in pa-
tients without contraindications for TA and TF access routes, and
to compare these to patients receiving TAo-TAVI as a last resort




ROUTE is a multicentre, multinational, prospective, observational
registry established using data from 18 centres across Europe
(NCT01991431) [11]. Patients were enrolled between February
2013 and February 2015. All patients included in the registry pro-
vided written informed consent, and ethical approval was ob-
tained from the relevant committees at each site.
Patients
Inclusion criteria were severe aortic stenosis; an indication for
TAVI as decided by a consensus of cardiac surgeons and cardi-
ologists; and eligibility for the SAPIEN XT or a SAPIEN 3 THV
(Edwards Lifesciences, Irvine, CA, USA) via the TAo access route
[11]. All patients included were scheduled to undergo TAVI via
the TAo approach, with this access route decision made by the
institutional interdisciplinary Heart Team consisting of cardiac
surgeons, cardiologists and anaesthesiologists; independently
from the registry.
Patients were excluded if they displayed congenital unicuspid/
bicuspid aortic valves; evidence of intra-cardiac mass, thrombus,
vegetation, active infection, or endocarditis; inability to tolerate
anticoagulation or antiplatelet agents; or excessive calcification of
the access site. Furthermore, patients who were scheduled to re-
ceive a simultaneous procedure, such as a coronary artery bypass
graft (CABG) were also excluded.
The decision to use the TAo approach was generally based on
one of two concepts: either (i) TAo-TAVI was the default proced-
ure preferred by the given centre, without having first excluded
the feasibility of TA and TF routes (at least one of which would
have been feasible) (first choice; TAo-first); or (ii) TAo-TAVI was
chosen as a last resort following the exclusion of TA and TF route
feasibility, which would otherwise have been the routes of prefer-
ence (neither TA nor TF feasible, last resort; TAo-last). Based on
the patient and procedural variables documented, patients were
stratified into two groups on a post-hoc basis: TAo-first (meeting
the criteria of decision concept 1) or TAo-last (meeting the crite-
ria of decision concept 2).
Statistical analysis
Complication rates were defined according to the Valve
Academic Research Consortium (VARC)-2 criteria [12]. Statistical
analysis was performed using SAS version 9.4 (SAS Institute Inc.).
Continuous variables are presented as means ± standard devi-
ations (SD). Categorical variables are presented as absolute num-
bers and percentages. For comparisons between the TAo-last
and TAo-first groups, the chi-square test or Fisher’s exact test was
used for categorical variables, and the t-test for continuous vari-
ables. The risk of overall 30-day mortality and other events dur-
ing the 30 days of follow-up were calculated using a logistic
model, which included age, gender, hypertension at baseline,
PVD or hostile PV anatomy at baseline, aortic valve peak gradient
[mmHg], and comorbidities potentially interfering with the access
decision as possible risk factors. No inferential testing was per-
formed and P-values reported are only of a descriptive nature.
RESULTS
A total of 309 patients were enrolled in ROUTE, of which 8 did
not meet the inclusion criteria (Fig. 1). Out of the remaining 301
patients, TAo-TAVI was chosen preferentially for 224 patients,
despite the heart team considering TA- and/or TF-TAVI to have
been feasible (TAo-first group; Table 1). Conversely, 77 patients
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underwent TAo-TAVI as a last resort based on the fact that the
heart team considered them ineligible for TF and TA access
routes due to contraindications (TAo-last group).
Patient characteristics
Patients in the TAo-first group had a mean age of 81.8 ± 5.9 years
and 56% were female (Table 1). The ejection fraction was
52.9 ± 11.7% at an aortic valve peak gradient of 69.3 ± 22.9 mmHg.
Symptoms were assessed as consistent with NYHA class III in 65%
and class IV in 11% of patients. Frequent comorbidities were
hypertension (74%), CAD (62%), and PVD/hostile PV anatomy
(47%). The mean STS score was 9.4 ± 8.3%. Cardiac and non-
cardiac comorbidities were found to be comparably frequent be-
tween the two groups, with the exception of hypertension, which
was reported less often in TAo-first than TAo-last patients (74% vs.
86%; P = 0.040).
Procedural characteristics
Ministernotomy was the preferred access route in 288 out of 300
patients (Table 2). The principal comorbidities that may poten-
tially have affected the access route decision in either group were
PVD (22% overall; 20% TAo-first; 27% TAo-last) and hostile vessel
status (19% overall; 9% TAo-first; 48% TAo-last).
The most frequently chosen valve size in the TAo-first group was
the 26 mm valve (48%), followed by the 23 mm (30%) and 29 mm
(22%) valves, with the SAPIEN XT used in 57% of cases. Pre-dilation
of the aortic valve was performed in 80% of patients (Table 3).
Compared to patients in the TAo-last group, TAo-first patients
underwent BAV more often (80% vs. 57%; P < 0.001) and had
shorter procedural durations (98.5 ± 32.7 min vs. 131.4 ± 40.4 min;
P < 0.001) and fluoroscopy times (11.5 ± 8.2 min vs. 14.9 ± 8.8 min;
P < 0.01).
Procedural outcomes
In TAo-first patients, the valve was successfully delivered and the
catheter retrieved in all patients (100%), with 99% of procedures
considered to have been device successes (including absence of
procedural mortality, correct positioning of a single bioprosthetic
heart valve, and absence of moderate or severe paravalvular regur-
gitation or residual stenosis with a mean gradient above 20 mmHg)
(Table 4). Periprocedural complications such as conversion to open
surgery (1% vs. 3%; P = 0.46; adjusted OR: 0.5; 95% CI: 0.0–6.2), re-
quirement for a second valve (1% vs. 3%; P = 0.46; adjusted OR: 0.4;
95% CI: 0.0–3.5), and permanent pacemaker implantation (5% vs.
1%; P = 0.30; adjusted OR: 6.2; 95% CI: 0.7–54.4;) were low and not
associated with the type of access decision (first vs. last) according
to multivariate analysis. The same was true for the rate of paravalvu-
lar regurgitation (3% vs. 2% >_moderate, respectively). One patient in
the TAo-last group with severe paravalvular leakage required reop-
eration in open surgery nine days after TAo-TAVI.
Post-procedure, the aortic valve peak pressure gradient in the
TAo-first group had fallen significantly relative to baseline (from
69.3 ± 22.9 to 17.5 ± 7.7 mmHg; P < 0.001) and was similar to that
of TAo-last patients (18.0 ± 7.9 mmHg; Fig. 2). There was a trend
towards a greater peak pressure reduction in the TAo-last group
(-59.6 mmHg vs. -51.8 mmHg; P = 0.055).
Overall, patients receiving TAo-TAVI were hospitalized for
9.9 ± 8.5 days with a mean stay in an intensive care unit (ICU) of
2.9 ± 5.7 days. No differences were seen between TAo-first com-
pared to TAo-last groups in terms of length of hospitalization
(9.6 ± 8.1 vs. 10.9 ± 9.7 days, respectively; P = 0.27) or ICU stay
(3.0 ± 6.4 vs. 2.8 ± 2.6 days, respectively; P = 0.80).
30-day follow-up
Rate of all-cause mortality at 30 days was 6% in the TAo-first
group, with a stroke rate of 2%, and life-threatening bleeding in
4% of patients (Table 5). Corresponding rates in the TAo-last
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group were comparable (5%, 0% and 3%, respectively), with no
differences between groups and no effects related to the type of
access decision (first vs. last) detected at multivariate analysis (ad-
justed for baseline characteristics). The same was true in terms of
an increase in creatinine, rate of MI, and valve-related dysfunc-
tion requiring a repeat procedure. Indeed, the only notable dif-
ference in 30-day outcomes was a higher rate of temporary
dialysis in TAo-last patients compared to TAo-first (11% vs. 3%;
P = 0.014). After adjusting for baseline parameters, multivariate
analysis also suggested that temporary dialysis was less likely in
the TAo-first condition (adjusted OR: 0.2; 95% CI: 0.0–0.8).
Early safety (defined as an absence of mortality, stroke, life-
threatening bleeding, acute kidney injury stage 2 and 3, coron-
ary obstruction, major vascular complication and valve-related
dysfunction requiring operation or reintervention) was 81% in
both groups (P ¼ 0.98). Clinical efficacy (defined as absence of
Table 1: Patient characteristics
TAo-first choice TAo-last resort P-value
N¼ 224 N¼ 77 (last vs. first)
(mean [SD] or n [%]) (mean [SD] or n [%])
Age [years] 81.8 ± 5.9 81.6 ± 6.1 0.82
Gender [% female] 125/224 (56) 37/77 (48) 0.24
Height [cm] 164.7 ± 10.2 164.8 ± 8.3 0.95
Weight [kg] 72.5 ± 17.6 71.3 ± 16.4 0.60
Current smoker 19/205 (9) 10/76 (1) 0.34
Cardiac characteristics
Ejection fraction [%] 52.9 ± 11.7 51.3 ± 13.8 0.36
Aortic valve peak gradient [mmHg] 69.3 ± 22.9 77.6 ± 23.4 0.02
Aortic valve mean gradient [mmHg] 44.3 ± 15.5 44.4 ± 14.9 0.95
NYHA class 0.58
Class I 6/222 (3) 1/77 (1)
Class II 47/222 (21) 18/77 (23)
Class III 145/222 (65) 46/77 (60)
Class IV 24/222 (11) 12/77 (16)
Cardiac comorbidities
CAD 138/224 (62) 46/77 (60) 0.77
Previous CABG 15/223 (7) 4/77 (5) 0.63
Previous MI 33(222 (15) 13/77 (17) 0.67
Other comorbidities
Hypertension 165/222 (74) 66/77 (86) 0.04
Diabetes Mellitus 58/222 (26) 21/77 (27) 0.84
PVD or hostile PV anatomy 105/224 (47) 23/77 (30) 0.01
COPD 48/222 (22) 16/76 (21) 0.84
Creatinine >_ 2.0 mg/dl 14/224 (6) 8/77 (10) 0.23
STS score [%] 9.4 ± 8.3 7.9 ± 4.8 0.14
Vmax: maximum velocity; NYHA: New York Heart Association; CAD: coronary artery disease; CABG: coronary artery bypass graft; MI: myocardial infarction;
PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease; STS: Society of Thoracic Surgeons; TAo: transaortic.
aFor comparison of all four NYHA classes.
Table 2: Access route
TAo-first choice TAo-last resort P-value
N¼ 224 N¼ 77 (last vs. first)
n [%] n [%]
Access <0.01
Ministernotomy 218/224 (98) 70/77 (91)
Right anterior thoracotomy 5/224 (2) 7/77 (9)
Comorbidities potentially interfering with access route decision <0.001
PVD 45/224 (20) 21/77 (27)
Vessel status 20/224 (9) 37/77 (48)
Significant respiratory disease 8/224 (4) 6/77 (8)
Poor LV function 3/224 (1) 5/77 (7)
Multiple re-do surgeries 4/224 (2) 0/77 (0)
High stroke risk 2/224 (1) 3/77 (4)
Chest wall deformity 1/224 (1) 1/77 (1)
PVD: peripheral vascular disease; LV: left ventricular; TAo: transaortic.
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mortality, stroke, rehospitalization, NYHA class III or IV, valve-
related dysfunction with mean residual gradient > 20 mmHg, or
moderate or severe paravalvular leak) was also similar between
the TAo-first and TAo-last groups (80% vs. 82%, respectively;
P = 0.73). At multivariate analysis, after adjusting for baseline
characteristics, no effect of the type of access decision (first
vs. last) was detected for either early safety (adjusted OR: 1.1;
95% CI: 0.5–2.5) or clinical efficacy (adjusted OR: 1.0; 95%
CI: 0.4–2.2).
DISCUSSION
The present analysis was performed to assess the feasibility
and safety of a first-line TAo-TAVI approach (TAo-first) under
routine clinical conditions. TAo-first patients were further
compared to those for whom TAo-TAVI was chosen only
because of contraindications to both the TA and TF access
routes, which is current practice at most sites. It was found
that first-line TAo-TAVI was highly successful, with low rates of
Table 3: Procedural characteristics
TAo-first choice TAo-last resort P-value
N¼ 224 N¼ 77 (last vs. first)
(mean [SD] or n [%]) (mean [SD] or n [%])
Valve size
23 mm 66/223 (30) 17/77 (22) 0.27
26 mm 108/223 (48) 37/77 (48)
29 mm 49/223 (22) 23/77 (30)
Valve type 0.55
SAPIEN XT 128/224 (57) 47/77 (61)
SAPIEN 3 96/224 (43) 30/77 (39)
Pre-TAVI balloon dilatation completed 178/223 (80) 44/77 (57) <0.001
Post-TAVI balloon dilatation 53/223 (24) 17/77 (22) 0.76
Duration of procedure [min] 98.5 ± 32.7 131.4 ± 40.4 <0.001
Fluoroscopy time [min] 11.5 ± 8.2 14.9±8.8 0.003
Volume of contrast agent [ml] 99.1 ± 44.5 111.7 ± 63.0 0.10
TAVI: transcatheter aortic valve implantation; TAo: transaortic.
aFor comparison of all valve sizes.
Table 4: Procedural outcomes
TAo-first choice TAo-last resort Univariable Multivariable
N¼ 224 N¼ 77 unadjusted adjustedc
(mean [SD] or n [%]) (mean [SD] or n [%]) OR (95%CI) OR (95%CI)
Valve delivered and catheter retrieved 220/220 (100)b 77/77 (100) n.a. n.a.
Device success 221/223 (99) 75/77 (97) 3.0 (0.4–21.3) 3.3 (0.3–31.7)
Conversion to open surgery 3/223 (1) 2/77 (3) 0.5 (0.1–3.1) 0.5 (0.0–6.2)
Second valve required 3/223 (1) 2/77 (3) 0.5 (0.1–3.1) 0.4 (0.0–3.5)
Atrioventricular block 13/223 (6) 2/77 (3) 2.3 (0.5–10.5) 2.0 (0.4–11.1)
Permanent pacemaker implantation 10/223 (5) 1/77 (1) 3.6 (0.5–28.3) 6.2 (0.7–54.4)
Access complications 5/223 (2) 1/77 (1) 1.7 (0.2–15.2) 1.3 (0.1–15.1)
Dissection 2/223 (1) 0/77 (0) n.a. n.a.
Rupture 1/223 (0) 1/77 (1) 0.3 (0.0–5.5) 0.3 (0.0–51.6)
Severe bleeding 3/223 (1) 0/77 (0) n.a. n.a.
Paravalvular regurgitation 0.6 (0.3–1.4)a n.a.
None/trace 171/223 (77) 62/77 (81)
Mild 44/223 (20) 13/77 (17)
Moderate 7/223 (3) 1/77 (1)
Severe 1/223 (0) 1/77 (1)
Central regurgitation 0.7 (0.1–3.5) n.a.
None/trace 212/223 (95) 74/77 (96)
Mild 11/223 (5) 3/77 (4)
Moderate 0 (0) 0 (0)
Severe 0 (0) 0 (0)
TAo: transaortic.
aFor comparison of all four grades of regurgitation.
bFor three patients no information was available.
cAdjusted for age adjusted for age, gender, hypertension at baseline, PVD or hostile PV anatomy at baseline, aortic valve peak gradient [mmHg] and comorbid-
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paravalvular regurgitation and permanent pacemaker implant-
ation. Thirty-day mortality was 6% and only 2% of the patients
suffered from stroke, with just 4% experiencing life-threatening
bleeding.
Baseline characteristics and comorbidities
potentially interfering with access route decision
In order to address all of the study aims, the registry gathered
data on preoperative patient characteristics as well as the clinical
decision pathway leading to the TAo-TAVI intervention. At base-
line, surgical risk and most comorbidities/disease parameters
were generally well balanced between groups. One (perhaps sur-
prising) difference was the proportion of patients found to have
PVD or hostile PV anatomy in each group, applying to only 30%
of patients in the TAo-last group compared to 47% of the TAo-
first group. However stratification into the two patient subsets
was based on overall feasibility (or lack thereof) and although
PVD sometimes precludes the use of TF access, it is neither the
sole reason nor always a contraindication. Indeed, there are
many PDV patients in clinical practice who are suitable for TF-
TAVI, such as those with obliterative disease of the thigh, inguinal
area or lower limb and those for whom minimal lumen diameter
is above 5.5 mm. Thus, it does not necessarily follow that half of
TAo-first patients automatically had contraindications to the TF
route, nor that clinical decision-making was inappropriate.
Procedural outcomes
Procedural outcomes were excellent in TAo-first patients, with all
patients having the valve delivered and the catheter retrieved.
Furthermore, the significant drop in peak pressure gradients
across the aortic valve suggest excellent efficacy of the prosthesis.
The finding that this reduction was nominally greater in TAo-last
patients is likely due to their higher baseline values for this vari-
able, rather than the conditions of the access route decision.
Complications included conversion to open surgery in three pa-
tients (1%), the requirement for a second valve (1%), AV block in
13 patients (6%) and pacemaker implantation in 10 patients (5%).
Moderate and severe paravalvular regurgitation was seen in 3%
and 0% of the patients, respectively. There numbers are all within
expectation.
The 26 mm valve was the most commonly used valve type in
TAo-first patients, which is in agreement with other studies re-
garding TF-, TA- and TAo-TAVI [5]. The mean duration of proced-
ure and fluoroscopy were found to be significantly shorter for
Figure 2: Aortic gradients. AV: aortic valve; TAo: transaortic.
Table 5: 30-day follow-up
TAo-first choice TAo-last resort Univariable Multivariable
N¼ 219 N¼ 74 unadjusted adjustede
n [%] n [%] OR (95%CI) OR (95%CI)
All-cause mortality 14/219 (6) 4/74 (5) 1.2 (0.4–3.8) 1.0 (0.3–3.8)
Stroke 4/219 (2) 0/74 (0) n.a. n.a.
Life-threatening bleeding 8/219 (4) 2/74 (3) 1.4 (0.3–6.6) 0.9 (0.2–5.0)
Acute kidney injurya
Temporary dialysis 7/216 (3) 8/71 (11) 0.3 (0.0–0.7) 0.2 (0.0–0.8)
Increase in creatinine b 4/213 (2) 1/70 (3) 1.3 (0.1–12.0) 0.7 (0.0–12.1)
Myocardial infarction 1/219 (1) 2/74 (3) 0.2 (0.0–1.8) 0.2 (0.0–4.4)
Major vascular complication 8/219 (4) 2/74 (3) 1.4 (0.3–6.6) 1.1 (0.2–6.7)
Valve-related dysfunction requiring repeat procedure 1/219 (1) 0/73 (0) n.a. n.a.
Permanent pacemaker implantation 23/220 (11) 3/74 (4) 2.8 (0.8–9.5) 2.6 (0.7–9.9)
Early safety c 179/220 (81) 60/74 (81) 1.0 (0.5–2.0) 1.1 (0.5–2.5)
Clinical efficacy d 176/219 (80) 60/73 (82) 1.1 (0.6–2.2) 1.0 (0.4–2.2)
aPatients with dialysis pre-intervention excluded.
bCreatinine increase of >_ 4.0 mg/dl or >_ 200% according to AKIN.
cEarly safety defined as absence of mortality, stroke, life-threatening bleeding, acute kidney injury stage 2 and 3, coronary obstruction, major vascular compli-
cation and valve-related dysfunction requiring operation or reintervention.
dClinical efficacy defined as absence of mortality, stroke, rehospitalization, NYHA class III or IV, valve-related dysfunction with mean residual
gradient > 20 mmHg, or moderate or severe paravalvular leak.
eAdjusted for age adjusted for age, gender, hypertension at baseline, PVD or hostile PV anatomy at baseline, aortic valve peak gradient [mmHg] and comorbid-
ities interfering with decision.
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the TAo-first group, whereas the reduced volume of contrast
agent did not reach statistical significance. This is likely due to
the greater experience of the surgeons that carried out the im-
plantation for the TAo-first group. The centres where these pa-
tients were enrolled used TAo access as their standard approach
and so would be more familiar with the technique in comparison
to the surgeons at the sites that only used TAo as a last resort.
While all surgeons that took part in the study underwent exten-
sive training, in addition to the requirement of having carried out
at least five TAo-TAVI procedures, a gap in the level of experi-
ence between centres was inevitable.
Paravalvular and central regurgitation rates were similar be-
tween the two groups, with more than 95% of patients being
classed as none/trace or mild. No patient was classified as having
moderate or severe central regurgitation, whereas moderate or
severe paravalvular regurgitation was reported in 2% vs. 3% of
patients in the TAo-last and TAo-first groups. These values are
comparable to the 4.6% and 2.9% previously reported for TAo-
TAVI [2, 8], the 2.3% and 2.2% reported for TA-TAVI [2], and the
1.5% and 6.6% reported for TF-TAVI [13]. Other studies also
noted similar rates of regurgitation; however, it is difficult to dir-
ectly compare values as different valve types were used and clas-
sification of this event is only qualitative and highly variable
between publications [5].
30-day outcomes
All-cause 30-day mortality was 6% for the TAo-first patients, with
rates for TAo-last patients being nominally lower (5%). The mor-
tality rates for TAo-TAVI reported in the literature range from
6.8–14% [3, 5, 7, 8]. For TA-TAVI on the other hand, 30-day mor-
tality has been documented to be slightly higher, with a range of
7.7–18.2% [3, 10], while the values for TF-TAVI are slightly lower
at 4.2–11.1% [9, 14]. Thus, the observed mortality rates for TAo-
first are at the lower end of what has been reported by other
data sources.
A permanent pacemaker was implanted in 11% of the TAo-
first patients, which was higher than the 4% documented for the
TAo-last cohort, without reaching statistical significance. These
rates vary between 2%–11.4% in the literature [5, 7, 8]. While val-
ues for TA-TAVI range from approximately 6.2%–11.6%, those for
TF-TAVI are generally below 7% [14]. Increased pacemaker rates
have been reported for the SAPIEN 3 vs the SAPIEN XT valves, al-
though the use of these valve types was not different between
groups. Implantation height, which was not recorded in the pre-
sent dataset, may be another explanatory variable, as has been
reported in a recent analysis of more than 577 patients receiving
either the SAPIEN XT or the SAPIEN 3 [15]. In this analysis, the
mean implantation height was significantly lower in patients
requiring pacemaker implantation (aortic/ventricular stent exten-
sion 67%/33% vs 72%/28%, respectively; P = 0.032). At multivari-
ate regression analysis, implantation height was the only
independent predictor of pacemaker implantation (OR 0.94; 95%
CI: 0.90–0.99; P < 0.01).
Acute kidney injury with need for temporary dialysis was diag-
nosed more often in the TAo-last group, and was the only vari-
able associated with the type of access route decision (first vs
last) at multivariate analysis. One reason for this effect may be
the differences in procedure time and volume of contrast agent
used. The rates of other complications during the 30-day follow-
up period were all low and roughly equivalent between the two
groups. Furthermore, they corresponded to those previously re-
ported for TAo-TAVI [7, 8].
Limitations
There were some limitations to the present analysis. Firstly, the
procedures carried out on TAo-last patients were performed at
institutions where TAo-TAVI was not the standard approach. As
such, the surgeons at these centres would inevitably have less ex-
perience in performing the implantation. The effect of this was
minimised by ensuring that all surgeons had completed at least
five TAo-TAVI procedures prior to taking part in the study.
Furthermore, every surgeon underwent extensive training ac-
cording to the Edwards Standard Operating Procedure. A second
limitation is the observational nature of the registry, meaning
that the decision to perform TAo-TAVI was made by an institu-
tional interdisciplinary Heart Team based on assessment of ana-
tomical and clinical conditions, likely resulting in two distinct
patient populations. Due to the nature of the clinical decision
required, it was not possible to provide randomized or risk-
adjusted data, and this may have been a source of bias during
comparisons. However, the observational aspect may also be
seen as an advantage, as it offers valuable insight into the real-
world rationale behind access route selection. Finally, there was a
low rate of adverse events during the 30-day follow-up period,
which makes it difficult to compare outcomes between the two
groups of patients. However, this demonstrates the excellent
safety of the TAo-TAVI approach.
CONCLUSIONS
Although comparative data to TA and TF procedures were not
available in the present analysis, the ROUTE registry provides
valuable data on the efficacy and safety of TAo as a first-line ac-
cess choice in patients with severe symptomatic aortic stenosis
undergoing TAVI. Findings suggest that TAo may be considered
not only as a last resort strategy when classical access routes are
deemed unfeasible, but also as a potential first-line option, with
only low rates of paravalvular regurgitation and permanent pace-
maker implantation. Future observational studies comparing
each of the alternative access routes as first-line procedures
would be useful.
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